Compare PIM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIM | EQ |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 89.4M |
| IPO Year | N/A | 2018 |
| Metric | PIM | EQ |
|---|---|---|
| Price | $2.99 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.56 |
| AVG Volume (30 Days) | 86.0K | ★ 571.8K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $60.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $1.30 |
| 52 Week High | $3.42 | $6.20 |
| Indicator | PIM | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 31.07 |
| Support Level | $2.97 | $1.30 |
| Resistance Level | $3.21 | $2.53 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 50.00 | 17.05 |
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.